Another Biogen-Ionis collab hits the dust after phase 1 ALS flop Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival 'Stay alive': Wave of layoffs crashes into biotech startup inferno Sponsored: How creative chemistry and collaboration synthesized a better drug strategy for Enterin Amylyx to answer for single-study ALS application at FDA advisory panel Verastem takes on debt to get RAS tumor program to finish line How snail venom could spawn new insulin, pain meds Senators ask GAO to examine Medicaid’s low COVID vaccination rates Abbott snags $1B U.S. government contract for rapid COVID-19 tests FDA halts use of GlaxoSmithKline and Vir's COVID-19 drug Xevudy in 8 northeast states Household-name Moderna rolls out a self-aware campaign for Spikevax vaccine NeuraLace taps new CEO to oversee rollout of nerve stimulation device for pain relief Featured Story | By Max Bayer Biogen and Ionis Pharmaceuticals are packing up and moving on after another antisense ALS candidate flopped in the clinic, less than six months after toferson failed. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Eli Lilly has turned over the cards on its $1.1 billion bid to challenge Sanofi and Regeneron’s Dupixent for the atopic dermatitis market. Analysts at Jefferies called the data compelling, although a hoped-for point of differentiation over the blockbuster incumbent has weakened. read more By Kyle LaHucik,Max Bayer,Annalee Armstrong At least 30 biopharmas have announced layoffs since September 2021, and the wave is likely to continue as thousands of startups struggle to stay above the competition. read more Sponsored by: Pfizer Reshaping the understanding of enteric nervous system (ENS) dysfunction and the progression of Parkinson’s, Pfizer CentreOne helped Enterin synthesize a better chemistry for its lead candidate. read more By Annalee Armstrong The single clinical trial Amylyx Pharmaceuticals presented to support approval of its ALS drug is “not exceptionally persuasive,” according to the briefing document the FDA released ahead of this week's planned advisory panel, which will review the treatment. read more By Nick Paul Taylor Down to its last $100 million, Verastem Oncology has taken on debt to try to get its lead program over the finish line. The deal sees Verastem tap Oxford Finance for a $150 million credit facility to fund trials in ovarian and non-small cell lung cancers and extend its cash runway through to 2025. read more By Sophia Sorensen Two studies from the University of Utah have made potential breakthroughs in fast-acting insulin production and somatostatin-analog pain meds from analyzing snail venom. read more By Phil Galewitz, Kaiser Health News Two prominent Democratic senators have requested a Government Accountability Office study of why COVID vaccination rates remain far lower among Medicaid enrollees than the general population. read more By Conor Hale The award is one of several steps toward the Biden administration’s redoubled goal of delivering 1 billion free tests to U.S. homes following the rise of the omicron variant. read more By Kevin Dunleavy The U.S. has paused the distribution of GlaxoSmithKline and Vir Biotechnology’s antibody drug Xevudy in the northeast, where the new omicron subvariant, BA.2, accounts for more than half of new infections. The states included in the directive are Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island and Vermont. read more By Ben Adams With Moderna's full approval for its COVID vaccine, Spikevax, comes a full-throttle approach to talking up its shot—and itself. read more By Andrea Park Less than a year after sewing up FDA clearance for its first nerve stimulation device, NeuraLace has brought on a new CEO to guide the clinical rollout of the Axon Therapy system. read more Resources Sponsored by: H1 Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now. Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 